Browsing Tag
Samsung Bioepis
7 posts
The inside story behind Samsung Bioepis’ European biosimilar takeover
Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars.
Biocon wins U.S. launch date for Prolia and Xgeva biosimilars—Can Amgen keep investors calm?
Amgen settles with Biocon for denosumab biosimilars, paving way for Bosaya and Aukelso U.S. launch from Oct 2025. What this means for biotech and investors.
Samsung Bioepis-NIPRO alliance boosts biosimilar pipeline in Japan’s $1.4B market
Samsung Bioepis (KRX: 207940) and NIPRO’s biosimilar partnership expands Japan market access amid rising healthcare costs and global biologics competition.
FDA grants approval to Samsung Bioepis’ Ospomyv and Xbryk, expanding access to biosimilar treatments for osteoporosis and cancer-related bone loss
The U.S. Food and Drug Administration (FDA) has approved Ospomyv™ and Xbryk™, two biosimilars developed by Samsung Bioepis…
Organon, Samsung Bioepis launch HUMIRA biosimilar HADLIMA in US
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible…
FDA accepts SB11 BLA for review: A step towards affordable treatment for retinal vascular disorders
The United States Food and Drug Administration (FDA) has recently accepted the biologics license application (BLA) for SB11,…
Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China
Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital…